back

About Mildronate®

Mildronate® (Meldonium) is a cardioprotective drug for the adjuvant treatment of patients with mild chronic cardiac insufficiency which improves a clinical status, functional capacity, and quality of life.

Therapeutic indications

Adjuvant treatment of mild chronic cardiac insufficiency.

Posology and method of administration*

Adults. The usual daily dose is 500-1000 mg of meldonium. The daily dose may be divided into two single doses. The maximum daily dose is 1000 mg. The treatment course varies from 4 to 6 weeks. For oral administration.

It is advised to use meldonium in the morning because of the possible stimulating effect. In order to avoid gastrointestinal disturbances, the medicinal product can be taken with food.

The effect on the cardiovascular system

Mildronate ® in combination with traditional treatment chronic heart failure

  • Increases tolerance to physical exertion and physical load size.
  • Strengthens the inotropic myocardium function.
  • Improves the quality of life of patients.

References

  1. Mildronate® SPaC. Summary of product characteristics (PDF file)
  2. Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity.